Will Elon Musk Buy a Nevada Lithium Mine?
With lithium prices so high, Elon Musk recently panic-tweeted about getting into the mining business to maintain his own Tesla battery metal supply. This lines up with the recent enactment of the Defense Production Act in March 2022 to ensure the strategic metals that are critical to the US and free world independence from China and Russia are produced in the US.
See the Latest Nevada Lithium Investing News
Ronald E. Blaylock, insider at Pfizer

Ronald E. Blaylock Insider Information

Director of Pfizer
Founder, Managing Partner of Gennx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006. Prior to launching Gennx360 Capital Partners, Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. Also held senior management positions at UBS, PaineWebber Group and Citicorp. Director of Advantage Solutions Inc., CarMax, Inc., and W.R. Berkley, Inc., an insurance holding company. Director of Urban One, Inc. from 2002 to 2019. Director of Syncreon U.S., a for-profit private company. Member of the Board of Trustees of Carnegie Hall. Member of the Board of Overseers of New York University Stern School of Business. Pfizer Director since 2017. Member of our Compensation and Audit Committees.

What is Ronald E. Blaylock's net worth?

The estimated net worth of Ronald E. Blaylock is at least $202,640.00 as of August 6th, 2020. Mr. Blaylock owns 4,000 shares of Pfizer stock worth more than $202,640 as of June 29th. This net worth estimate does not reflect any other assets that Mr. Blaylock may own. Learn More about Ronald E. Blaylock's net worth.

How do I contact Ronald E. Blaylock?

The corporate mailing address for Mr. Blaylock and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Ronald E. Blaylock's contact information.

Has Ronald E. Blaylock been buying or selling shares of Pfizer?

Ronald E. Blaylock has not been actively trading shares of Pfizer during the last ninety days. Most recently, 0 shares of the stock in a transaction dated Wednesday, June 29th. Learn More on Ronald E. Blaylock's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Frank D'Amelio (EVP), Jennifer Damico (SVP), Jennifer Damico (SVP), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 276,647 shares worth more than $14,190,373.18. The most recent insider tranaction occured on June, 7th when SVP Jennifer B Damico sold 4,218 shares worth more than $227,603.28. Insiders at Pfizer own 0.1 % of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 6/7/2022.

Ronald E. Blaylock Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/6/2020Buy13,000$38.55$501,150.004,000View SEC Filing Icon  
See Full Table

Ronald E. Blaylock Buying and Selling Activity at Pfizer

This chart shows Ronald E Blaylock's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $50.66
Low: $50.41
High: $51.97

50 Day Range

MA: $50.49
Low: $46.53
High: $53.99

2 Week Range

Now: $50.66
Low: $38.82
High: $61.71

Volume

15,581,883 shs

Average Volume

29,501,258 shs

Market Capitalization

$284.25 billion

P/E Ratio

11.62

Dividend Yield

3.08%

Beta

0.76
Lithium Triangle a "Treasure Trove" for the Popular Energy Metal
Lithium is the most precious commodity of the green revolution, and experts predict an exploding demand for the energy metal. Surrounded by multi-billion dollar assets, one little-known small-cap company in a renowned location in South America may become a strong link in the lithium supply chain due to a monster acquisition.
Put this company on your radar now.